Loading...
•
Jun 30, 2024
Theravance Q2 2024 Earnings Report
Reported financial and operational results for the second quarter of 2024.
Key Takeaways
Theravance Biopharma's YUPELRI net sales decreased 1% from the prior quarter. The company is exploring opportunities to unlock value from its Irish tax assets. Patent litigation is pending against four companies.
YUPELRI net sales decreased 1% from the prior quarter.
CYPRESS study enrollment is expected to complete in mid-2025.
TRELEGY had an exceptional quarter.
Exploring opportunities to unlock value from Irish tax assets.
Revenue by Segment
Revenue by Geographic Location
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...